BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chennews2025-02-28T12:51:27+00:00February 28th, 2025|Endpoints News|
Lilly joins molecular glue field with Magnet deal worth up to $1.25Bnews2025-02-28T11:30:58+00:00February 28th, 2025|Endpoints News|
Verve is latest gene editing company to suffer setback, as Vertex walks away from pactnews2025-02-27T16:24:04+00:00February 27th, 2025|Endpoints News|
Lilly pays $10M upfront for Organovo’s FXR agonist programnews2025-02-25T15:48:14+00:00February 25th, 2025|Endpoints News|
BridGene nets another Takeda deal amid plans to raise more funding and go publicnews2025-02-25T13:00:10+00:00February 25th, 2025|Endpoints News|
Pfizer wants in on Summit’s goal to beat Keytruda via ADC combosnews2025-02-24T12:18:40+00:00February 24th, 2025|Endpoints News|
Bluebird bio to sell to investment funds after struggling to make money from gene therapiesnews2025-02-21T16:34:08+00:00February 21st, 2025|Endpoints News|
Kevin Tang’s Concentra tries to disrupt proposed Acelyrin-Alumis mergernews2025-02-21T09:54:23+00:00February 21st, 2025|Endpoints News|
How Keymed steered the China-to-US NewCo model in biotechnews2025-02-20T16:20:44+00:00February 20th, 2025|Endpoints News|
AstraZeneca buys FibroGen’s China unit for local control of anemia drugnews2025-02-20T12:35:47+00:00February 20th, 2025|Endpoints News|
